Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthetic Biologics appoints Michael Kaleko scientific director

This article was originally published in Scrip

Executive Summary

Synthetic Biologics, a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, has named Dr Michael Kaleko scientific director. Dr Kaleko has worked in the gene therapy field since its inception in the 1980s, and until 2010 served as CSO of a company he co-founded in 2002 and sold in 2005, Advanced Vision Therapies. Prior to that, he co-directed research for 11 years at Genetic Therapy, a Novartis company.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC017080

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel